| Structure of the model
In brief, the model compares maintenance dialysis with each transplantation option to determine cost per quality-adjusted life-year 
| Data sources

| Clinical data
Deidentified registry data in the United States Renal Data System (USRDS) and patient-level data from the SRTR (kidney transplantations between January 1, 2005, and December 31, 2015) were used to estimate the time to primary nonfunction, graft failure, and posttransplantation mortality based on donor characteristics, as well as mortality on dialysis in the simulation cohort (Table 1) .
These data were supplemented with survival data from a large clinical cohort of ILDKT recipients. To address uncertainty, Weibull distributions were assumed for these time-to-event variables by using SRTR data as well as published data for ABOi LDKT and ILDKT.
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The distribution for death on dialysis was assumed to be the same for patients who were waitlisted and those who returned to dialysis at the time of graft failure. Because these distributions are nonGaussian, we present scale factors and shape rather than mean and SD values. Mean 5-year death and graft failure rates using these distributions were compared with observed data and presented as Table 1 in the supplemental digital content. Health state utility scores were drawn from a comprehensive literature review of dialysis and kidney transplantation and modeled as distributions. 
| Economic data
Two sources were combined to estimate the healthcare resource use associated with transplantation in this analysis, which, in general, assumes a payer perspective. Medicare claims data were obtained from the USRDS, which includes payment data for all patients receiving maintenance renal replacement therapy with Medicare as their primary insurance, including professional charges and payments for hospitalizations.
14 Medicare claims data (between January 1, 2003, and December 31, 2012) were queried to determine expected monthly costs after transplantation stratified by donor type (deceased/living), KDPI, and immunologic/blood group compatibility. Medicare payments were chosen to measure pretransplantation costs including maintenance dialysis and death on dialysis.
Multivariate risk-adjusted models were developed to estimate the cost of posttransplantation care, graft failure, and death after transplantation, as a function of organ quality for transplant recipients for those grafts.
Because Medicare diagnosis-related group (DRG)-based payments are poorly correlated with the actual cost of the transplantation procedure, we used estimates from a novel data set linking national registry data and hospital cost-accounting data from the University HealthSystem Consortium corporation, as per previous methods. 14 These data were queried to determine the cost of hospitalization for the transplantation procedure, stratified by donor source, organ quality, and the need for additional therapy. Cost ranges are shown in Table 2 and include estimates for low-KDPI 
| Simulation
DES was used to model patients' progression. [17] [18] [19] In DES modeling, occurrence of clinical events is defined as time to event, as drawn from distributions based on population data. Time to event distributions for key clinical events varied by donor type and organ characteristics (Table 1) . Both QALYs and costs were discounted to present values by using an annual rate of 3%. Model results were obtained by using 20 000 simulations, which produced stable results. Given the nature of DES simulation analysis, no measures of statistical significance can be reported. Cost per QALY and the incremental cost-effectiveness ratio (ICER) were calculated by comparing each transplantation option with dialysis.
| Ethics
Analyses of national registry and linked data sets were covered by the Saint Louis University Institutional Review Board. The data re- and in no way should be seen as an official policy or interpretation of the US government.
| RE SULTS
During the 10-year study period, transplantation was associated with a significant improvement in expected survival ( Figure 3 ). After adjustment for the difference in quality of life among patients on dialysis, maintenance dialysis therapy results in 4.03 QALYs over 10 years (Table 3 ). In comparison, deceased donor transplantation was associated with significant increases in quality-adjusted sur-
vival. Transplantation with low-KDPI and PHS increased-risk kid-
neys was predicted to increase average survival by 50% (6.07 and (Table S2 ).
| D ISCUSS I ON
Kidney transplantation is widely cited as a unique example of a medical therapy that is both cost-saving and life extending. Our study demonstrates a more complex relationship between cost and outcomes by using DES analysis. LDKT is cost-saving, as recipients of these transplants live longer and incur fewer costs. Low-KPDI DDKT is cost equivalent; however, it is highly cost-effective as patient survival is improved by 50%. High-KDPI DDKT and immunologically complex LDKT are slightly more expensive than dialysis. However, the survival advantage of kidney transplantation over dialysis is so substantial that all options including ILDKT are cost-effective, as expenditures per QALY are less than the current willingness to pay threshold of $100 000 per QALY. as well as estimated economic value of return to work after transplantation, despite data suggesting that few patients actually return to employment after kidney transplantation. 22 Our current analysis suggests that although the absolute economic benefit is less than estimated in some studies, compatible LDKT is indeed the dominant strategy for patients with advanced kidney disease. ABOi transplantation, while more expensive, is cost-effective and should be strongly considered as an option for appropriate candidates.
Currently, ILDKT offers substantial survival benefits, with a cost per QALY that is higher than dialysis but remains below $100 000
per QALY.
The clinical benefit of deceased donor transplantation was demonstrated initially by Wolfe and colleagues and confirmed in multiple subsequent studies. 2 However, at the time of the landmark study, donor selection was conservative, waiting times were shorter, and recipients were generally younger than in contemporary practices. The use of older, higher-risk, deceased donors has clear benefits in appropriate populations. Merion et al. demonstrated a benefit of expanded criteria donor kidneys for patients with diabetes, extended waiting times, and older age. 23 Massie and colleagues reported similar results using the newer KDPI scoring system. 6 While they are beneficial, the economic impact of these organs on patients and payers has not been well studied. Englesbe reported that expanded criteria donor kidneys were associated with net financial loss for the transplant program. 8 Similarly, we previously reported that higher-risk deceased donor organs were associated with higher costs and that Medicare payments did not compensate for these expenditures.
14 The higher costs were due to longer length of stay, higher rates of delayed graft function, and greater pharmaceutical costs. This cost differential may be contributing to rising discard rates for high-risk donor organs.
24-26
These data confirm an economic benefit for DDKT. Low-KDPI organs were demonstrated to yield a significantly lower cost per QALY than maintenance dialysis. Total costs over 10 years were nearly equivalent; however, median survival at 10 years was estimated to be 30% higher after DDKT and quality of life is improved after transplantation. Thus, kidney transplantation results in a more favorable cost per year of survival ratio and a cost per QALY well below the $100 000 threshold. High-KDPI DDKT remained costeffective, despite higher costs resulting from increased incidence of primary nonfunction, initial transplantation cost, and rate of return to dialysis.
While it is widely believed that kidney transplantation is costsaving compared with dialysis, these data reflect transplantation in an era of restrictive donor and recipient selection. In this study, only lLDKT and deceased donor transplantation with low-KDPI kidneys were at least cost equivalent at 10 years. In the current era of decreasing reimbursement for dialysis, increasing cost of transplantation, and growing donor complexity, it is likely that the economic benefits of kidney transplantation will be more limited.
These data demonstrate the benefit of increased overall rates of transplantation, which can best be achieved by increasing living donation and reducing deceased donor discard rates. Clearly, the economic benefits of LDKT would justify an economic incentive for living donation, should there be an ethically acceptable vehicle for this to be delivered. Similarly, efforts to increase the use of high-KDPI kidneys appear warranted as they appear to be both clinically and economically beneficial. Despite this observation, the discard rate of deceased donor kidneys has increased recently from 12.9% to 15.7%. 24 Factors associated with higher rates of discard include age, biopsy, donation after cardiac death, serology results (eg, hepatitis C virus infection), blood group, and terminal creatinine. Pulsatile perfusion was demonstrated to reduce discard rates. These factors also correlated with a higher cost of transplantation due to in- 
